prevention of exacerbations using pharmacological and non-pharmacological interventions (e.g. pulmonary rehabilitation and strategies aimed at improving physical activity). The book’s originality lies in the fact that it covers AEs in various respiratory diseases, allowing comparisons between definitions, short- and long-term consequences, triggers and therapeutic management. As such, this book will serve as a complete and up-to-date reference that will raise awareness on the importance of exacerbations in patients with chronic lung diseases and will promote further research in this area. Disclosures: P-R. Burgel has received personal fees from the following, outside the submitted work: AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Novartis, Vertex, Aptalis and Zambon. M. Contoli reports receiving a grant from GlaxoSmithKline during the conduct of the study and a grant from Chiesi outside the submitted work. M. Contoli reports receiving personal fees from the following, outside the submitted work: Chiesi, AstraZeneca, Boehringer Ingelheim, Chiesi, AstraZeneca, Novartis, Menarini, Mundipharma, Almirall and Zambon. xviii
Previous Page Next Page